- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-4690
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Update on Aplaviroc: An HIV Entry Inhibitor Targeting CCR5 ; volume:2 ; number:1 ; day:8 ; month:12 ; year:2005 ; pages:1 ; date:12.2005
Retrovirology ; 2, Heft 1 (8.12.2005), 1, 12.2005
- Beteiligte Personen und Organisationen
-
Demarest, James F.
SpringerLink (Online service)
- DOI
-
10.1186/1742-4690-2-S1-S13
- URN
-
urn:nbn:de:1111-2016080653570
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Demarest, James F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Validation of an enhanced sensitivity Trofile™ HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5
Clinical use of CCR5 inhibitors in HIV and beyond
HIV-1 Escape From Small Molecule CCR5 Inhibitors In Vitro
Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders
Entry inhibitors in HIV therapy
Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor
Lysosomotropic agents as HCV entry inhibitors
Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application
Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis
Vicriviroc, A Novel CCR5 Inhibitor, is NOT A p-glycoprotein Substrate In Vitro
Peptides targeting caspase inhibitors
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
Validation of an enhanced sensitivity Trofile™ HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5
Clinical use of CCR5 inhibitors in HIV and beyond
HIV-1 Escape From Small Molecule CCR5 Inhibitors In Vitro
Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders
Entry inhibitors in HIV therapy
Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor
Lysosomotropic agents as HCV entry inhibitors
Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application
Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis
Vicriviroc, A Novel CCR5 Inhibitor, is NOT A p-glycoprotein Substrate In Vitro
Peptides targeting caspase inhibitors
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
Validation of an enhanced sensitivity Trofile™ HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5
Clinical use of CCR5 inhibitors in HIV and beyond
HIV-1 Escape From Small Molecule CCR5 Inhibitors In Vitro
Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders
Entry inhibitors in HIV therapy
Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor
Lysosomotropic agents as HCV entry inhibitors
Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application
Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis
Vicriviroc, A Novel CCR5 Inhibitor, is NOT A p-glycoprotein Substrate In Vitro
Peptides targeting caspase inhibitors